These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22440858)

  • 1. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
    Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.
    Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M
    ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286
    [No Abstract]   [Full Text] [Related]  

  • 4. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.
    Kaiser M; Milbradt AG; Siciliano C; Assfalg-Machleidt I; Machleidt W; Groll M; Renner C; Moroder L
    Chem Biodivers; 2004 Jan; 1(1):161-73. PubMed ID: 17191784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
    Groll M; Götz M; Kaiser M; Weyher E; Moroder L
    Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors: Dozens of molecules and still counting.
    de Bettignies G; Coux O
    Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
    Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
    Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinyl ester-based cyclic peptide proteasome inhibitors.
    Baldisserotto A; Marastoni M; Fiorini S; Pretto L; Ferretti V; Gavioli R; Tomatis R
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1849-54. PubMed ID: 18294845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel fluorinated pseudopeptides as proteasome inhibitors.
    Formicola L; Maréchal X; Basse N; Bouvier-Durand M; Bonnet-Delpon D; Milcent T; Reboud-Ravaux M; Ongeri S
    Bioorg Med Chem Lett; 2009 Jan; 19(1):83-6. PubMed ID: 19041239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
    Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
    Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
    Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
    Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.
    Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M
    J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
    Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
    J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
    Tsukamoto S; Yokosawa H
    Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition.
    Kaiser M; Groll M; Renner C; Huber R; Moroder L
    Angew Chem Int Ed Engl; 2002 Mar; 41(5):780-3. PubMed ID: 12491334
    [No Abstract]   [Full Text] [Related]  

  • 17. Linear TMC-95-based proteasome inhibitors.
    Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J
    J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
    Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
    Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cyclic peptide proteasome inhibitors.
    Baldisserotto A; Marastoni M; Gavioli R; Tomatis R
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1966-9. PubMed ID: 19250821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereocontrolled synthesis of the northern part of potent proteasome inhibitor TMC-95A.
    Inoue M; Furuyama H; Sakazaki H; Hirama M
    Org Lett; 2001 Sep; 3(18):2863-5. PubMed ID: 11529776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.